Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Bio-Techne is a life sciences tools company supplying reagents, instruments, and services to pharmaceutical, biotech, and academic research labs globally. The company operates through Protein Sciences (antibodies, cytokines, growth factors), Diagnostics & Genomics (spatial biology platforms like GeoMx, molecular diagnostics), and Protein Platforms (Western blot systems, cell culture media). Its competitive moat stems from a catalog of 750,000+ research reagents, sticky customer relationships in drug discovery workflows, and proprietary spatial biology technology enabling multi-omic tissue analysis.
Bio-Techne generates revenue through consumable reagent sales (high-margin, recurring) and capital equipment placements (instruments create installed base for consumable pull-through). The business model relies on scientists' workflow integration—once researchers validate antibodies or adopt spatial biology platforms, switching costs are high due to protocol standardization and data continuity needs. Protein Sciences operates as a catalog business with 64.8% gross margins driven by proprietary antibody clones and limited competition for niche targets. Diagnostics & Genomics monetizes through instrument sales ($250K-$500K for GeoMx/CosMx systems) followed by consumable kits generating 3-5x instrument revenue over system lifetime. Pricing power stems from lack of alternatives for validated research-grade reagents and first-mover advantage in spatial transcriptomics.
Spatial biology instrument placements (GeoMx DSP, CosMx SMI) and consumable attachment rates—key growth driver as pharma adopts spatial profiling in drug development
Protein Sciences organic growth rates—reflects underlying health of biopharma R&D spending and academic research funding (NIH budgets)
Gross margin trajectory—mix shift toward higher-margin consumables vs. lower-margin instruments, pricing discipline in competitive segments
Acquisition integration execution—Bio-Techne pursues tuck-in M&A to expand reagent catalog and technology platforms; integration missteps impact profitability
China revenue exposure (~15-20% of sales)—geopolitical tensions, local competition, and COVID-related lab shutdowns create volatility
Spatial biology commoditization—competitors (10x Genomics, Vizgen/Bruker, Akoya) aggressively developing competing platforms with lower pricing and improved throughput, risking Bio-Techne's first-mover advantage in GeoMx/CosMx
China localization and geopolitical decoupling—Chinese government policies favoring domestic life sciences suppliers (BGI, Sino Biological) could erode Bio-Techne's 15-20% China revenue as labs substitute local alternatives
Antibody validation standards—increasing scrutiny of research reagent reproducibility and calls for stricter validation could require costly re-characterization of 750K+ catalog products
Thermo Fisher Scientific and Danaher (Abcam acquisition) consolidating antibody market with broader portfolios and cross-selling leverage into larger installed bases
10x Genomics' Xenium platform gaining traction in spatial transcriptomics with simpler workflow and lower cost-per-sample economics than CosMx
Private equity-backed competitors (Proteintech, Antibodies.com) offering aggressive pricing on commodity antibodies, compressing margins in Protein Sciences segment
Acquisition integration risk—Bio-Techne's growth strategy relies on tuck-in M&A; overpaying for targets or failing to achieve synergies could destroy value (historical precedent with ExoSome Diagnostics write-down)
Operating margin recovery uncertainty—path from 8.4% current operating margin back to historical 25%+ levels depends on spatial biology scale and cost discipline; prolonged investment phase could disappoint investors expecting margin expansion
moderate - Revenue tied to biopharma R&D budgets and academic research funding, which exhibit lag to GDP cycles. During recessions, large pharma maintains drug pipelines (defensive), but biotech funding contracts as venture capital tightens and IPO markets close. Academic labs face grant funding pressure when government budgets are constrained. However, life sciences tools are mission-critical inputs—labs reduce headcount before cutting reagent purchases. COVID demonstrated counter-cyclical potential as pandemic research drove demand surge, though normalization created 2023-2024 headwinds.
Rising rates negatively impact Bio-Techne through two channels: (1) Biotech customer funding—higher rates reduce venture capital availability and public biotech valuations, causing smaller customers to delay instrument purchases and reduce reagent orders. Series A/B biotech financings contracted 60%+ in 2022-2023 rate hiking cycle. (2) Valuation multiple compression—as growth stock trading at 7.7x sales, Bio-Techne's P/S multiple contracts when risk-free rates rise and investors rotate from growth to value. Minimal direct impact from debt (0.17 D/E ratio) but customer financing conditions dominate. Lower rates stimulate biotech funding and expand valuation multiples.
Low direct credit exposure given minimal debt and strong 4.54 current ratio. However, customer credit conditions matter significantly—biotech customers rely on venture debt and equity financing to fund operations. Tightening credit markets cause biotech failures (cash runway exhaustion), reducing Bio-Techne's addressable customer base. Large pharma customers (50%+ of revenue) have investment-grade credit and are insulated. Academic customers depend on federal grant funding, not credit markets. Overall credit sensitivity is indirect through biotech ecosystem health.
growth - Investors attracted to life sciences tools secular growth (biopharma R&D spending CAGR 5-7%), spatial biology market expansion (TAM $5B+ by 2030), and M&A-driven portfolio expansion. However, -56% net income decline and 8.4% operating margins suggest company is in investment/transition phase, requiring patience for profitability inflection. Recent -10.2% one-year return reflects growth-to-value rotation and biotech funding headwinds. Quality-growth investors focus on durable competitive moats (reagent catalog, spatial biology IP) and long-term margin recovery potential.
moderate-high - Beta likely 1.1-1.3 given correlation to biotech sector volatility and growth stock characteristics. Stock moves on quarterly spatial biology adoption updates, biopharma M&A cycles (pharma acquires biotech customers), and China geopolitical headlines. Earnings volatility elevated due to lumpy instrument placements and acquisition-related charges. 42.1x EV/EBITDA valuation creates downside risk if growth disappoints or rates rise further.
